Eli Lilly says its anti-obesity pill matches Ozempic

Eli Lilly's Orforglipron, an anti-obesity pill, demonstrated significant weight loss and blood sugar reduction in clinical trials, rivaling Novo Nordisk's Ozempic. The company plans to submit Phase-III trial data to regulators by year-end, anticipating approvals from 2026. The 36 mg dose resulted in an average weight loss of 7.9% over 40 weeks.